Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
BT-549 Pictilisib
1.0
pan PI3K
PI3K/mTOR
 0.6824 0.02370
BT-549 Pictilisib
3.1623
pan PI3K
PI3K/mTOR
 0.4939 0.02234
BT-549 Pictilisib
10.0
pan PI3K
PI3K/mTOR
 0.1463 0.10436
BT-549 Ceritinib
0.001
ALK
RTK
 1.0354 -0.00205
BT-549 Ceritinib
0.0031623
ALK
RTK
 1.0486 -0.00465
BT-549 Ceritinib
0.01
ALK
RTK
 1.0588 -0.00192
BT-549 Ceritinib
0.031623
ALK
RTK
 1.0205 -0.00162
BT-549 Ceritinib
0.1
ALK
RTK
 0.9916 -0.00112
BT-549 Ceritinib
0.31623
ALK
RTK
 0.9864 0.00346
BT-549 Ceritinib
1.0
ALK
RTK
 0.9084 0.00935
BT-549 Ceritinib
3.1623
ALK
RTK
 0.4584 0.08731
BT-549 Ceritinib
10.0
ALK
RTK
 -0.2284 0.38436
BT-549 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0178 0.00620
BT-549 Neratinib
0.001
EGFR/HER2
RTK
 1.0264 0.00386
BT-549 Neratinib
0.0031623
EGFR/HER2
RTK
 0.9834 0.00771
BT-549 Neratinib
0.01
EGFR/HER2
RTK
 1.0671 -0.00187
BT-549 Neratinib
0.031623
EGFR/HER2
RTK
 1.0088 0.00774
BT-549 Neratinib
0.1
EGFR/HER2
RTK
 0.9646 -0.00745
BT-549 Neratinib
0.31623
EGFR/HER2
RTK
 0.9148 0.00585
BT-549 Neratinib
1.0
EGFR/HER2
RTK
 0.7989 0.00295
BT-549 Neratinib
3.1623
EGFR/HER2
RTK
 0.2081 0.10152
BT-549 Tivantinib
0.001
MET
RTK
 1.0263 -0.00269
BT-549 Tivantinib
0.0031623
MET
RTK
 1.0218 0.00415
BT-549 Tivantinib
0.01
MET
RTK
 1.0764 -0.00650
BT-549 Tivantinib
0.031623
MET
RTK
 1.0445 0.00898